Boehringer Ingelheim’s Jascayd (nerandomilast) has been recommended for marketing authorization by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency for the treatment… read more.
Genentech has received FDA approval of Ocrevus (ocrelizumab) intravenous (IV) infusion for the treatment of relapsing-remitting multiple sclerosis (RRMS) in pediatric patients 10 years of age and older who… read more.
Pfizer announced positive topline results from the Phase 3 MagnetisMM-5 study evaluating Elrexfio (elranatamab) as monotherapy in adults with relapsed or refractory multiple myeloma (RRMM) who received at… read more.
AstraZeneca’s Baxfendy (baxdrostat) has been approved in the US as a first-in-class aldosterone synthase inhibitor (ASI) for the treatment of hypertension in combination with other antihypertensive medications, to… read more.
Gilead Sciences, Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending the marketing… read more.
Guardant Health announced that the FDA has approved Guardant360 Liquid CDx, advancing blood-based comprehensive genomic testing by integrating genomic and epigenomic insights and helping clinicians make better-informed treatment… read more.
Roche announced that it has received CE Mark for Elecsys pTau217, a blood test developed in collaboration with Eli Lilly and Company and designed to measure the phosphorylated… read more.
Novo Nordisk is presenting a new sub-analysis from the large clinical trial STEP UP at the European Congress on Obesity (ECO) on 12-15 May in Istanbul, Türkiye, showing… read more.
BridgeBio Pharma, Inc. announced new data from the Phase III ATTRibute-CM study at Heart Failure 2026, organized by the Heart Failure Association of the European Society of Cardiology… read more.
ImmunityBio announced results from two indirect treatment comparison (ITC) analyses presented at the 2026 American Urological Association (AUA) Annual Meeting evaluating nogapendekin alfa inbakicept-pmln (NAI, Anktiva) plus Bacillus Calmette–Guérin (BCG)… read more.
Krystal Biotech announced that, on May 15, 2026, the United Kingdom MHRA granted marketing authorization to Vyjuvek (beremagene geperpavec-svdt) for the treatment of wounds in patients with dystrophic epidermolysis… read more.
Gilead Sciences, Inc. (Nasdaq: GILD) will present findings from 29 abstracts, including late-breaking presentations at the European Association for the Study of the Liver (EASL) Congress, May 27-30,… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
